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methods for scale-up. Using evidence from Nkwanta, national scale-up was 
launched in 2000 as a program of exchanges for district teams to work with 
Navrongo and Nkwanta implementers on designing pilot implementation of 
CHPS elsewhere in Ghana. RESULTS: This paper reviews operational 
determinants of this success and implications of the Upper East Region 
experience for efforts to develop evidence-based community health services 
elsewhere in Africa CONCLUSIONS: Although CHPS scale-up has been launched 
in all 170 districts, the Upper East Region remains its lead performing region, 
despite challenging economic, ecological, and social circumstances for health 
development.  
 
PHP161  
PHARMACOECONOMICS: NEED TO IMPLEMENT AS A TOOL FOR DRUG 
REIMBURSEMENT IN INDIA  
Janodia M1, Udupa N2, Muragundi PM3, Ligade V4, Dharmagadda S4 
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Manipal 
College of Pharmaceutical Sciences, Manipal, India, 3Manipal College of Pharmaceutical  
Sciences, Manipal, Karnataka, India, 4Manipal College of Pharmceutical Sciences, Manipal, India, 
India  
Health care is one of India’s largest sectors. Private and Public sector spending in 
India is highly skewed towards the private sector accounting for nearly 80% of 
total health care spending in India. However, a major chunk is through out of 
pocket (OOP) expenditure whereas only 11% of population has health insurance. 
About 35% of population is covered by state or central health insurance schemes. 
The public health spending is comparatively low. As a percentage of GDP the 
public health spending has reduced from 1.3% in 1990 to 0.9%. The overall budget 
on drugs and medicines by both central and state governments is only a fraction 
of health sector expenditure. The state expenditure is also not uniform as some 
states are spending about 5% on medicines whereas other states are spending as 
high as 17% on medicines and drugs. Despite these disparities in drug and 
medicine spending among states in India, it is reported that public institutions 
spend inadequate in India. Though the government of India has ceiling on drug 
prices of about 76 drugs, many drugs are out of control and for same drug offered 
by different companies’ different price exist. Due to differences in price of 
various brands of same molecule, access to health care is not uniform. This is an 
issue during reimbursement of drugs. Private health insurance companies do not 
have a list of medicines that would be reimbursed. Thus, private health 
insurance players reimburse different amount to different patients for same 
molecule with different brand names. If pharmacoeconomics is applied as a tool 
to identify the best treatment option, the burden on health care would reduce  
for all stakeholders including patients, insurance companies and the 
government.  
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ORGANIZATION: The Development for society (DFS) is an non Governmental 
organization working in undivided KBK districts of Odisha in the area of Health, 
Nutrition, WASH including quality assurance & patient safety in hospitals at 
community level. OBJECTIVES: Patient safety is the absence of preventable harm to 
a patient during the process of health care. The discipline of patient safety is the 
coordinated efforts to prevent harm, caused by the process of health care itself, 
from occurring to patients. The data on frequency and magnitude of avoidable 
adverse patient events in Odisha is not well known. The goal is to create a data base 
on frequency and magnitude of avoidable adverse patient safety events for further 
intervention to improve quality of care. METHODS: Surgical Safety; Hand Hygiene; 
Management of Medication and Patient communication. RESULTS: DFS in 
collaboration with Indian Confederation for Healthcare Accreditation and other 
partners like WHO, patients group, Ministry of Health would create data base on 
patient safety, spell out clear-cut patient safety standards, train employees of 
hospitals (Primary health centres) including doctors & paramedics, ASHA 
(accredited social health activist) at village level, local nursing homes and clinics in 
spotting medical errors and adverse reactions as well as encourage them to report 
the same in order to create a "desi" database and to take suitable mitigation 
measures. CONCLUSION: The Patient safety data created would help in designing 
the standards which would be implemented on pilot basis in KBK districts of 
Odisha with support from Ministry of Health, Government of Odisha & other 
development partners including patient groups which would help in improving the 
quality of care in the PHCs of this regions thereby improving the health care quality 
in the hospitals (PHCs) at community level.  
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OBJECTIVES: The study examined cardiovascular safety of concurrent atypical 
antipsychotic agents and long acting stimulants (LAS) use in children and 
adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). METHODS: 
The study involved retrospective longitudinal analysis of 2003-2007 Medicaid 
Analytical eXtract (MAX) data of four US states. The cohort involved children and 
adolescents aged 6 to 17 years who initiated treatment with LAS for ADHD. The 
continuous eligibility 6 months before and 12 months after the index LAS date 
was ensured for the study cohort. Atypical antipsychotic use was identified after 
the initiation of the index LAS and classified as current use (days of active use), 
former use (days after current use), and nonuse (time before the first use 
including the follow up of those who never exposed to atypicals). The study end 
point was defined as the first inpatient or outpatient claim due to cardiovascular 
event. The risk for cardiovascular event was evaluated using time dependent 
Cox regression analysis. RESULTS: All the study participants were followed for 
9,206,873 person-days of observation period. The numbers of cardiac events were 
840, 202, and 45 during periods of atypical non-use, current use, and former use 
respectively. After controlling for demographic, service related, and clinical 
characteristics, the study found that current users and former users of atypical 
antipsychotics were not associated with cardiovascular events compared to no 
atypical users (Current use: HR, 1.17, 95% CI, 0.98-1.40; Former use: HR, 1.24; 95% 
CI, 0.91-1.69). However, patient characteristics like diagnosis of obesity and 
diabetes, and use of mood stabilizers increased the risk of cardiovascular events. 
CONCLUSIONS: The study did not find any increased cardiovascular risk with 
addition of the atypical antipsychotics to long acting stimulant regimen in 
children and adolescents diagnosed with ADHD.  
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OBJECTIVES: To conduct a systematic review and meta-analysis to better 
quantify the real-world incidence of in-hospital or 30-day death or myocardial 
infarction (MI) following coronary stent thrombosis (ST), as well as ST-related 
treatment costs. METHODS: We searched Medline, Embase and Scopus from 
January 2000 to July 2012 to identify observational or registry studies that 
evaluated a cohort of ≥25 patients experiencing angiographically-confirmed 
thrombosis of a drug-eluting or bare-metal stent, required the use of dual-
antiplatelet therapy for guideline recommended durations, and reported on the 
incidence of in-hospital or 30-day death or MI and/or ST-related treatment costs. 
Incidences and treatment costs from each study were pooled using random-
effects meta-analysis. Statistical heterogeneity was assessed using the I2statistic 
(>50% deemed significant). RESULTS: A total of 23 studies were included. Among 
the 12 studies (N=8,832 STs) reporting in-hospital mortality, the pooled incidence 
rate was estimated to be 7.9%, 95%CI=5.4%-11.3%, I2=86%. Ten studies (N=1,294 
STs) reported 30-day death, with a pooled incidence of 11.6%, 95%CI=8.8%-15.1%, 
I2=55%. Subgroup analysis suggested patients experiencing early ST (within 30-
days of implant) had higher in-hospital and 30-day mortality than those 
experiencing very-late ST (interaction p<0.04 for both). Stent type (bare-metal vs. 
drug-eluting) had no significant effect on in-hospital or 30-day mortality 
(interaction p>0.22 for both). In the 5 studies (N=542 STs) and 3 studies (N=180 
STs) reporting in-hospital and 30-day MI, respectively, the pooled incidence rates 
were 6.1%, 95%CI=2.1%-16.2%, I2=88% and 9.5%, 95%CI=3.8%-22.0%, I2=65%. Only 
one study reported costs associated with ST, estimating the median/patient cost 
of hospitalization to treat early ST at $11,134 (in 2000US$). CONCLUSIONS: 
Regardless of stent type used, the short-term clinical and economic 
consequences of coronary stent thrombosis (ST) appear significant. While stent 
type does not seem to affect the incidence of post-ST outcomes, an earlier 
occurrence of ST may be associated with higher mortality.  
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OBJECTIVES: While patients use Chinese medications (CM) concurrently with 
Western medications are common in Taiwan, the use of CM products with 
antiplatelet agents might increase the bleeding risks. The objective of this 
research was to explore the impact of major bleeding risk due to concurrent use 
of antiplatelet drugs with CMs ( American ginseng, Asian ginseng, danshen, and 
dong quai). METHODS: A nested case-control and case-crossover study using the 
2007 National Health Insurance Research Databases in Taiwan was conducted. 
All outpatients who used aspirin, clopidogrel, dipyridamole, or ticlopidine 
continuously were included in the cohort. Those antiplatelet users hospitalized 
for major bleeding were in case group and the corresponding control group was 
randomly matched base on the propensity score. The case periods in case-
crossover study were defined as 1-14 days before hospitalization and 15-28 days 
or 71-84 days before hospitalization were control periods. The conditional 
logistic regression analyses were performed to determine the associations 
between major bleeding and exposure to interactions between antiplatelets and 
specific CM. RESULTS: Of the 92,046 antiplatelet users as the cohort, 1,095 
patients (1.19%) were identified as cases and 887 patients were included in the 
case-crossover study. Concurrent use of antiplatelet drugs with specific single 
CM showed an increased risk of hospitalization due to major bleeding in both 
studies but was not statistically significant. Antiplatelet drugs users were 28% to 
152% more risk of major bleeding among those who used Asian ginseng or 
danshen currently than others. CONCLUSIONS: Relationship between major 
bleeding and concurrent use of antiplatelet drugs with CM was not ascertained. 
The adverse clinical outcomes due to concomitant use warrant further 
investigation.  
